Alendronate and pharmacological doses of 1alpha OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia

J Bone Miner Metab. 2002;20(3):170-3. doi: 10.1007/s007740200024.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alendronate / therapeutic use*
  • Bone and Bones / diagnostic imaging
  • Calcium Compounds / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Fibrous Dysplasia, Polyostotic / complications
  • Fibrous Dysplasia, Polyostotic / diagnostic imaging
  • Fibrous Dysplasia, Polyostotic / drug therapy*
  • Fibrous Dysplasia, Polyostotic / metabolism
  • Humans
  • Hydroxycholecalciferols / therapeutic use*
  • Hypophosphatemia / diagnostic imaging
  • Hypophosphatemia / drug therapy*
  • Hypophosphatemia / metabolism
  • Lactates / therapeutic use
  • Phosphates / therapeutic use
  • Radionuclide Imaging

Substances

  • Calcium Compounds
  • Hydroxycholecalciferols
  • Lactates
  • Phosphates
  • calcium lactate
  • alfacalcidol
  • Alendronate